Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) gapped down prior to trading on Wednesday . The stock had previously closed at $22.82, but opened at $22.26. Teva Pharmaceutical Industries shares last traded at $21.19, with a volume of 13093245 shares.

A number of analysts have recently weighed in on TEVA shares. Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $25.00 to $23.00 in a report on Friday, September 7th. Leerink Swann upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and boosted their target price for the stock from $16.00 to $24.00 in a report on Monday, October 1st. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 target price on the stock in a report on Monday, October 1st. Cantor Fitzgerald set a $25.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, September 14th. Finally, Mizuho boosted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, September 17th. Five research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $21.68.

The firm has a market cap of $21.90 billion, a P/E ratio of 5.39, a PEG ratio of 1.61 and a beta of 0.71. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.64 by $0.14. The company had revenue of $4.70 billion for the quarter, compared to the consensus estimate of $4.75 billion. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The firm’s revenue was down 17.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.02 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd will post 2.68 EPS for the current year.

In related news, EVP Sven Dethlefs acquired 2,000 shares of the stock in a transaction on Friday, August 3rd. The stock was bought at an average cost of $21.92 per share, with a total value of $43,840.00. Following the transaction, the executive vice president now directly owns 6,445 shares in the company, valued at $141,274.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $22.70, for a total transaction of $94,545.50. Following the completion of the sale, the executive vice president now directly owns 8,290 shares of the company’s stock, valued at $188,183. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,350 shares of company stock valued at $239,430. 0.43% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Wealthstreet Investment Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $200,000. MAI Capital Management purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $204,000. Greenleaf Trust purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $215,000. Rehmann Capital Advisory Group lifted its position in shares of Teva Pharmaceutical Industries by 136.2% in the 2nd quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock worth $219,000 after purchasing an additional 5,201 shares during the period. Finally, Court Place Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $220,000. 64.51% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What is a Call Option?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.